secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001493152-23-007763
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX borrows $10M from Juvenescence, lends to Serina; Dr. West resigns from board
--------------------------------------------------------------------------------

- Entered $10M secured convertible note with Juvenescence; proceeds used to purchase $10M Serina note.
- Juvenescence note matures March 2026; 7% origination fee; convertible into AgeX common stock after merger or March 2024.
- Dr. Michael D. West resigned from AgeX board but remains CEO; expected to transition to CEO of subsidiary Reverse Bio after spinoff.
- Potential merger with Serina and spinoff of Reverse Bio are under consideration but no definitive agreements executed yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer